Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy Agents in Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Selinexor (Primary) ; Capecitabine; Carboplatin; Cyclophosphamide; Doxorubicin; Eribulin; Fluorouracil; Irinotecan; Olaparib; Oxaliplatin; Paclitaxel; Pembrolizumab; Pemetrexed; Topotecan
- Indications Cancer
- Focus Adverse reactions
- 20 Jun 2017 Planned number of patients changed from 470 to 588.
- 20 Jun 2017 Status changed from active, no longer recruiting to recruiting.
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology